Drug-drug Interaction Study With Metformin and Imatinib
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study will address the following question: Does imatinib influence the pharmacokinetics
of metformin in healthy volunteers? Recent studies in the Giacomini laboratory have indicated
that imatinib may block metformin elimination from the kidney by inhibiting organic cation
transporter efflux of metformin. 1. The investigators hypothesize that the addition of
imatinib to metformin therapy will reduce the renal clearance (CLR) of metformin leading to
increased plasma concentrations and risk for toxicities 2. Knowledge of the pharmacokinetic
interaction profile of metformin with organic cation transporter inhibitors, such as
imatinib, is important to help develop safer more effective drug therapy with reduced side
effects.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
National Institute of General Medical Sciences (NIGMS) National Institutes of Health (NIH)